- call +1-201-465-4211
- email sales@marketquest.biz
- Call +1-201-465-4211
- Email: sales@marketquest.biz
According to our latest study, the global Candida Infections Drugs market size was valued at USD million in 2022 and is forecast to a readjusted size of USD million by 2029 with a CAGR of % during review period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
Candida infection is a yeast infection where the skin acts as a host organism, and the infection multiplies and grows with the period. Candida albicans are the most common species of this infection. Candida normally lives on the skin and inside the body, such as the throat, gut, mouth, and vagina, without causing problems. It can cause infections if it grows out of control or enters deep into the body.
This report is a detailed and comprehensive analysis for global Candida Infections Drugs market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2023, are provided.
Key Features:
Global Candida Infections Drugs market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2018-2029
Global Candida Infections Drugs market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2018-2029
Global Candida Infections Drugs market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2018-2029
Global Candida Infections Drugs market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (US$/Unit), 2018-2023
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Candida Infections Drugs
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Candida Infections Drugs market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include F. Hoffmann-La Roche Ltd, Mylan NV, Teva Pharmaceutical Industries Ltd, Sanofi and Pfizer Inc, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.
Market Segmentation
Candida Infections Drugs market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Azole
Nystatin
Other
Market segment by Application
Beriberi
Jock Itch
Vaginal Infection
Other
Major players covered
F. Hoffmann-La Roche Ltd
Mylan NV
Teva Pharmaceutical Industries Ltd
Sanofi
Pfizer Inc
GSK plc
Novartis AG
AstraZeneca
Johnson & Johnson Private Limited
Sun Pharmaceutical Industries Ltd
Merck & Co., Inc
Bristol-Myers Squibb Company
Lilly
Amgen Inc
Market segment by region, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Candida Infections Drugs product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Candida Infections Drugs, with price, sales, revenue and global market share of Candida Infections Drugs from 2018 to 2023.
Chapter 3, the Candida Infections Drugs competitive situation, sales quantity, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Candida Infections Drugs breakdown data are shown at the regional level, to show the sales quantity, consumption value and growth by regions, from 2018 to 2029.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2018 to 2029.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value and market share for key countries in the world, from 2017 to 2022.and Candida Infections Drugs market forecast, by regions, type and application, with sales and revenue, from 2024 to 2029.
Chapter 12, market dynamics, drivers, restraints, trends, Porters Five Forces analysis, and Influence of COVID-19 and Russia-Ukraine War.
Chapter 13, the key raw materials and key suppliers, and industry chain of Candida Infections Drugs.
Chapter 14 and 15, to describe Candida Infections Drugs sales channel, distributors, customers, research findings and conclusion.
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
1 Market Overview
1.1 Product Overview and Scope of Candida Infections Drugs
1.2 Market Estimation Caveats and Base Year
1.3 Market Analysis by Type
1.3.1 Overview: Global Candida Infections Drugs Consumption Value by Type: 2018 Versus 2022 Versus 2029
1.3.2 Azole
1.3.3 Nystatin
1.3.4 Other
1.4 Market Analysis by Application
1.4.1 Overview: Global Candida Infections Drugs Consumption Value by Application: 2018 Versus 2022 Versus 2029
1.4.2 Beriberi
1.4.3 Jock Itch
1.4.4 Vaginal Infection
1.4.5 Other
1.5 Global Candida Infections Drugs Market Size & Forecast
1.5.1 Global Candida Infections Drugs Consumption Value (2018 & 2022 & 2029)
1.5.2 Global Candida Infections Drugs Sales Quantity (2018-2029)
1.5.3 Global Candida Infections Drugs Average Price (2018-2029)
2 Manufacturers Profiles
2.1 F. Hoffmann-La Roche Ltd
2.1.1 F. Hoffmann-La Roche Ltd Details
2.1.2 F. Hoffmann-La Roche Ltd Major Business
2.1.3 F. Hoffmann-La Roche Ltd Candida Infections Drugs Product and Services
2.1.4 F. Hoffmann-La Roche Ltd Candida Infections Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.1.5 F. Hoffmann-La Roche Ltd Recent Developments/Updates
2.2 Mylan NV
2.2.1 Mylan NV Details
2.2.2 Mylan NV Major Business
2.2.3 Mylan NV Candida Infections Drugs Product and Services
2.2.4 Mylan NV Candida Infections Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.2.5 Mylan NV Recent Developments/Updates
2.3 Teva Pharmaceutical Industries Ltd
2.3.1 Teva Pharmaceutical Industries Ltd Details
2.3.2 Teva Pharmaceutical Industries Ltd Major Business
2.3.3 Teva Pharmaceutical Industries Ltd Candida Infections Drugs Product and Services
2.3.4 Teva Pharmaceutical Industries Ltd Candida Infections Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.3.5 Teva Pharmaceutical Industries Ltd Recent Developments/Updates
2.4 Sanofi
2.4.1 Sanofi Details
2.4.2 Sanofi Major Business
2.4.3 Sanofi Candida Infections Drugs Product and Services
2.4.4 Sanofi Candida Infections Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.4.5 Sanofi Recent Developments/Updates
2.5 Pfizer Inc
2.5.1 Pfizer Inc Details
2.5.2 Pfizer Inc Major Business
2.5.3 Pfizer Inc Candida Infections Drugs Product and Services
2.5.4 Pfizer Inc Candida Infections Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.5.5 Pfizer Inc Recent Developments/Updates
2.6 GSK plc
2.6.1 GSK plc Details
2.6.2 GSK plc Major Business
2.6.3 GSK plc Candida Infections Drugs Product and Services
2.6.4 GSK plc Candida Infections Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.6.5 GSK plc Recent Developments/Updates
2.7 Novartis AG
2.7.1 Novartis AG Details
2.7.2 Novartis AG Major Business
2.7.3 Novartis AG Candida Infections Drugs Product and Services
2.7.4 Novartis AG Candida Infections Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.7.5 Novartis AG Recent Developments/Updates
2.8 AstraZeneca
2.8.1 AstraZeneca Details
2.8.2 AstraZeneca Major Business
2.8.3 AstraZeneca Candida Infections Drugs Product and Services
2.8.4 AstraZeneca Candida Infections Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.8.5 AstraZeneca Recent Developments/Updates
2.9 Johnson & Johnson Private Limited
2.9.1 Johnson & Johnson Private Limited Details
2.9.2 Johnson & Johnson Private Limited Major Business
2.9.3 Johnson & Johnson Private Limited Candida Infections Drugs Product and Services
2.9.4 Johnson & Johnson Private Limited Candida Infections Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.9.5 Johnson & Johnson Private Limited Recent Developments/Updates
2.10 Sun Pharmaceutical Industries Ltd
2.10.1 Sun Pharmaceutical Industries Ltd Details
2.10.2 Sun Pharmaceutical Industries Ltd Major Business
2.10.3 Sun Pharmaceutical Industries Ltd Candida Infections Drugs Product and Services
2.10.4 Sun Pharmaceutical Industries Ltd Candida Infections Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.10.5 Sun Pharmaceutical Industries Ltd Recent Developments/Updates
2.11 Merck & Co., Inc
2.11.1 Merck & Co., Inc Details
2.11.2 Merck & Co., Inc Major Business
2.11.3 Merck & Co., Inc Candida Infections Drugs Product and Services
2.11.4 Merck & Co., Inc Candida Infections Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.11.5 Merck & Co., Inc Recent Developments/Updates
2.12 Bristol-Myers Squibb Company
2.12.1 Bristol-Myers Squibb Company Details
2.12.2 Bristol-Myers Squibb Company Major Business
2.12.3 Bristol-Myers Squibb Company Candida Infections Drugs Product and Services
2.12.4 Bristol-Myers Squibb Company Candida Infections Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.12.5 Bristol-Myers Squibb Company Recent Developments/Updates
2.13 Lilly
2.13.1 Lilly Details
2.13.2 Lilly Major Business
2.13.3 Lilly Candida Infections Drugs Product and Services
2.13.4 Lilly Candida Infections Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.13.5 Lilly Recent Developments/Updates
2.14 Amgen Inc
2.14.1 Amgen Inc Details
2.14.2 Amgen Inc Major Business
2.14.3 Amgen Inc Candida Infections Drugs Product and Services
2.14.4 Amgen Inc Candida Infections Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.14.5 Amgen Inc Recent Developments/Updates
3 Competitive Environment: Candida Infections Drugs by Manufacturer
3.1 Global Candida Infections Drugs Sales Quantity by Manufacturer (2018-2023)
3.2 Global Candida Infections Drugs Revenue by Manufacturer (2018-2023)
3.3 Global Candida Infections Drugs Average Price by Manufacturer (2018-2023)
3.4 Market Share Analysis (2022)
3.4.1 Producer Shipments of Candida Infections Drugs by Manufacturer Revenue ($MM) and Market Share (%): 2022
3.4.2 Top 3 Candida Infections Drugs Manufacturer Market Share in 2022
3.4.2 Top 6 Candida Infections Drugs Manufacturer Market Share in 2022
3.5 Candida Infections Drugs Market: Overall Company Footprint Analysis
3.5.1 Candida Infections Drugs Market: Region Footprint
3.5.2 Candida Infections Drugs Market: Company Product Type Footprint
3.5.3 Candida Infections Drugs Market: Company Product Application Footprint
3.6 New Market Entrants and Barriers to Market Entry
3.7 Mergers, Acquisition, Agreements, and Collaborations
4 Consumption Analysis by Region
4.1 Global Candida Infections Drugs Market Size by Region
4.1.1 Global Candida Infections Drugs Sales Quantity by Region (2018-2029)
4.1.2 Global Candida Infections Drugs Consumption Value by Region (2018-2029)
4.1.3 Global Candida Infections Drugs Average Price by Region (2018-2029)
4.2 North America Candida Infections Drugs Consumption Value (2018-2029)
4.3 Europe Candida Infections Drugs Consumption Value (2018-2029)
4.4 Asia-Pacific Candida Infections Drugs Consumption Value (2018-2029)
4.5 South America Candida Infections Drugs Consumption Value (2018-2029)
4.6 Middle East and Africa Candida Infections Drugs Consumption Value (2018-2029)
5 Market Segment by Type
5.1 Global Candida Infections Drugs Sales Quantity by Type (2018-2029)
5.2 Global Candida Infections Drugs Consumption Value by Type (2018-2029)
5.3 Global Candida Infections Drugs Average Price by Type (2018-2029)
6 Market Segment by Application
6.1 Global Candida Infections Drugs Sales Quantity by Application (2018-2029)
6.2 Global Candida Infections Drugs Consumption Value by Application (2018-2029)
6.3 Global Candida Infections Drugs Average Price by Application (2018-2029)
7 North America
7.1 North America Candida Infections Drugs Sales Quantity by Type (2018-2029)
7.2 North America Candida Infections Drugs Sales Quantity by Application (2018-2029)
7.3 North America Candida Infections Drugs Market Size by Country
7.3.1 North America Candida Infections Drugs Sales Quantity by Country (2018-2029)
7.3.2 North America Candida Infections Drugs Consumption Value by Country (2018-2029)
7.3.3 United States Market Size and Forecast (2018-2029)
7.3.4 Canada Market Size and Forecast (2018-2029)
7.3.5 Mexico Market Size and Forecast (2018-2029)
8 Europe
8.1 Europe Candida Infections Drugs Sales Quantity by Type (2018-2029)
8.2 Europe Candida Infections Drugs Sales Quantity by Application (2018-2029)
8.3 Europe Candida Infections Drugs Market Size by Country
8.3.1 Europe Candida Infections Drugs Sales Quantity by Country (2018-2029)
8.3.2 Europe Candida Infections Drugs Consumption Value by Country (2018-2029)
8.3.3 Germany Market Size and Forecast (2018-2029)
8.3.4 France Market Size and Forecast (2018-2029)
8.3.5 United Kingdom Market Size and Forecast (2018-2029)
8.3.6 Russia Market Size and Forecast (2018-2029)
8.3.7 Italy Market Size and Forecast (2018-2029)
9 Asia-Pacific
9.1 Asia-Pacific Candida Infections Drugs Sales Quantity by Type (2018-2029)
9.2 Asia-Pacific Candida Infections Drugs Sales Quantity by Application (2018-2029)
9.3 Asia-Pacific Candida Infections Drugs Market Size by Region
9.3.1 Asia-Pacific Candida Infections Drugs Sales Quantity by Region (2018-2029)
9.3.2 Asia-Pacific Candida Infections Drugs Consumption Value by Region (2018-2029)
9.3.3 China Market Size and Forecast (2018-2029)
9.3.4 Japan Market Size and Forecast (2018-2029)
9.3.5 Korea Market Size and Forecast (2018-2029)
9.3.6 India Market Size and Forecast (2018-2029)
9.3.7 Southeast Asia Market Size and Forecast (2018-2029)
9.3.8 Australia Market Size and Forecast (2018-2029)
10 South America
10.1 South America Candida Infections Drugs Sales Quantity by Type (2018-2029)
10.2 South America Candida Infections Drugs Sales Quantity by Application (2018-2029)
10.3 South America Candida Infections Drugs Market Size by Country
10.3.1 South America Candida Infections Drugs Sales Quantity by Country (2018-2029)
10.3.2 South America Candida Infections Drugs Consumption Value by Country (2018-2029)
10.3.3 Brazil Market Size and Forecast (2018-2029)
10.3.4 Argentina Market Size and Forecast (2018-2029)
11 Middle East & Africa
11.1 Middle East & Africa Candida Infections Drugs Sales Quantity by Type (2018-2029)
11.2 Middle East & Africa Candida Infections Drugs Sales Quantity by Application (2018-2029)
11.3 Middle East & Africa Candida Infections Drugs Market Size by Country
11.3.1 Middle East & Africa Candida Infections Drugs Sales Quantity by Country (2018-2029)
11.3.2 Middle East & Africa Candida Infections Drugs Consumption Value by Country (2018-2029)
11.3.3 Turkey Market Size and Forecast (2018-2029)
11.3.4 Egypt Market Size and Forecast (2018-2029)
11.3.5 Saudi Arabia Market Size and Forecast (2018-2029)
11.3.6 South Africa Market Size and Forecast (2018-2029)
12 Market Dynamics
12.1 Candida Infections Drugs Market Drivers
12.2 Candida Infections Drugs Market Restraints
12.3 Candida Infections Drugs Trends Analysis
12.4 Porters Five Forces Analysis
12.4.1 Threat of New Entrants
12.4.2 Bargaining Power of Suppliers
12.4.3 Bargaining Power of Buyers
12.4.4 Threat of Substitutes
12.4.5 Competitive Rivalry
12.5 Influence of COVID-19 and Russia-Ukraine War
12.5.1 Influence of COVID-19
12.5.2 Influence of Russia-Ukraine War
13 Raw Material and Industry Chain
13.1 Raw Material of Candida Infections Drugs and Key Manufacturers
13.2 Manufacturing Costs Percentage of Candida Infections Drugs
13.3 Candida Infections Drugs Production Process
13.4 Candida Infections Drugs Industrial Chain
14 Shipments by Distribution Channel
14.1 Sales Channel
14.1.1 Direct to End-User
14.1.2 Distributors
14.2 Candida Infections Drugs Typical Distributors
14.3 Candida Infections Drugs Typical Customers
15 Research Findings and Conclusion
16 Appendix
16.1 Methodology
16.2 Research Process and Data Source
16.3 Disclaimer
List of Tables
Table 1. Global Candida Infections Drugs Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Table 2. Global Candida Infections Drugs Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
Table 3. F. Hoffmann-La Roche Ltd Basic Information, Manufacturing Base and Competitors
Table 4. F. Hoffmann-La Roche Ltd Major Business
Table 5. F. Hoffmann-La Roche Ltd Candida Infections Drugs Product and Services
Table 6. F. Hoffmann-La Roche Ltd Candida Infections Drugs Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 7. F. Hoffmann-La Roche Ltd Recent Developments/Updates
Table 8. Mylan NV Basic Information, Manufacturing Base and Competitors
Table 9. Mylan NV Major Business
Table 10. Mylan NV Candida Infections Drugs Product and Services
Table 11. Mylan NV Candida Infections Drugs Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 12. Mylan NV Recent Developments/Updates
Table 13. Teva Pharmaceutical Industries Ltd Basic Information, Manufacturing Base and Competitors
Table 14. Teva Pharmaceutical Industries Ltd Major Business
Table 15. Teva Pharmaceutical Industries Ltd Candida Infections Drugs Product and Services
Table 16. Teva Pharmaceutical Industries Ltd Candida Infections Drugs Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 17. Teva Pharmaceutical Industries Ltd Recent Developments/Updates
Table 18. Sanofi Basic Information, Manufacturing Base and Competitors
Table 19. Sanofi Major Business
Table 20. Sanofi Candida Infections Drugs Product and Services
Table 21. Sanofi Candida Infections Drugs Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 22. Sanofi Recent Developments/Updates
Table 23. Pfizer Inc Basic Information, Manufacturing Base and Competitors
Table 24. Pfizer Inc Major Business
Table 25. Pfizer Inc Candida Infections Drugs Product and Services
Table 26. Pfizer Inc Candida Infections Drugs Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 27. Pfizer Inc Recent Developments/Updates
Table 28. GSK plc Basic Information, Manufacturing Base and Competitors
Table 29. GSK plc Major Business
Table 30. GSK plc Candida Infections Drugs Product and Services
Table 31. GSK plc Candida Infections Drugs Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 32. GSK plc Recent Developments/Updates
Table 33. Novartis AG Basic Information, Manufacturing Base and Competitors
Table 34. Novartis AG Major Business
Table 35. Novartis AG Candida Infections Drugs Product and Services
Table 36. Novartis AG Candida Infections Drugs Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 37. Novartis AG Recent Developments/Updates
Table 38. AstraZeneca Basic Information, Manufacturing Base and Competitors
Table 39. AstraZeneca Major Business
Table 40. AstraZeneca Candida Infections Drugs Product and Services
Table 41. AstraZeneca Candida Infections Drugs Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 42. AstraZeneca Recent Developments/Updates
Table 43. Johnson & Johnson Private Limited Basic Information, Manufacturing Base and Competitors
Table 44. Johnson & Johnson Private Limited Major Business
Table 45. Johnson & Johnson Private Limited Candida Infections Drugs Product and Services
Table 46. Johnson & Johnson Private Limited Candida Infections Drugs Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 47. Johnson & Johnson Private Limited Recent Developments/Updates
Table 48. Sun Pharmaceutical Industries Ltd Basic Information, Manufacturing Base and Competitors
Table 49. Sun Pharmaceutical Industries Ltd Major Business
Table 50. Sun Pharmaceutical Industries Ltd Candida Infections Drugs Product and Services
Table 51. Sun Pharmaceutical Industries Ltd Candida Infections Drugs Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 52. Sun Pharmaceutical Industries Ltd Recent Developments/Updates
Table 53. Merck & Co., Inc Basic Information, Manufacturing Base and Competitors
Table 54. Merck & Co., Inc Major Business
Table 55. Merck & Co., Inc Candida Infections Drugs Product and Services
Table 56. Merck & Co., Inc Candida Infections Drugs Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 57. Merck & Co., Inc Recent Developments/Updates
Table 58. Bristol-Myers Squibb Company Basic Information, Manufacturing Base and Competitors
Table 59. Bristol-Myers Squibb Company Major Business
Table 60. Bristol-Myers Squibb Company Candida Infections Drugs Product and Services
Table 61. Bristol-Myers Squibb Company Candida Infections Drugs Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 62. Bristol-Myers Squibb Company Recent Developments/Updates
Table 63. Lilly Basic Information, Manufacturing Base and Competitors
Table 64. Lilly Major Business
Table 65. Lilly Candida Infections Drugs Product and Services
Table 66. Lilly Candida Infections Drugs Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 67. Lilly Recent Developments/Updates
Table 68. Amgen Inc Basic Information, Manufacturing Base and Competitors
Table 69. Amgen Inc Major Business
Table 70. Amgen Inc Candida Infections Drugs Product and Services
Table 71. Amgen Inc Candida Infections Drugs Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 72. Amgen Inc Recent Developments/Updates
Table 73. Global Candida Infections Drugs Sales Quantity by Manufacturer (2018-2023) & (K Units)
Table 74. Global Candida Infections Drugs Revenue by Manufacturer (2018-2023) & (USD Million)
Table 75. Global Candida Infections Drugs Average Price by Manufacturer (2018-2023) & (US$/Unit)
Table 76. Market Position of Manufacturers in Candida Infections Drugs, (Tier 1, Tier 2, and Tier 3), Based on Consumption Value in 2022
Table 77. Head Office and Candida Infections Drugs Production Site of Key Manufacturer
Table 78. Candida Infections Drugs Market: Company Product Type Footprint
Table 79. Candida Infections Drugs Market: Company Product Application Footprint
Table 80. Candida Infections Drugs New Market Entrants and Barriers to Market Entry
Table 81. Candida Infections Drugs Mergers, Acquisition, Agreements, and Collaborations
Table 82. Global Candida Infections Drugs Sales Quantity by Region (2018-2023) & (K Units)
Table 83. Global Candida Infections Drugs Sales Quantity by Region (2024-2029) & (K Units)
Table 84. Global Candida Infections Drugs Consumption Value by Region (2018-2023) & (USD Million)
Table 85. Global Candida Infections Drugs Consumption Value by Region (2024-2029) & (USD Million)
Table 86. Global Candida Infections Drugs Average Price by Region (2018-2023) & (US$/Unit)
Table 87. Global Candida Infections Drugs Average Price by Region (2024-2029) & (US$/Unit)
Table 88. Global Candida Infections Drugs Sales Quantity by Type (2018-2023) & (K Units)
Table 89. Global Candida Infections Drugs Sales Quantity by Type (2024-2029) & (K Units)
Table 90. Global Candida Infections Drugs Consumption Value by Type (2018-2023) & (USD Million)
Table 91. Global Candida Infections Drugs Consumption Value by Type (2024-2029) & (USD Million)
Table 92. Global Candida Infections Drugs Average Price by Type (2018-2023) & (US$/Unit)
Table 93. Global Candida Infections Drugs Average Price by Type (2024-2029) & (US$/Unit)
Table 94. Global Candida Infections Drugs Sales Quantity by Application (2018-2023) & (K Units)
Table 95. Global Candida Infections Drugs Sales Quantity by Application (2024-2029) & (K Units)
Table 96. Global Candida Infections Drugs Consumption Value by Application (2018-2023) & (USD Million)
Table 97. Global Candida Infections Drugs Consumption Value by Application (2024-2029) & (USD Million)
Table 98. Global Candida Infections Drugs Average Price by Application (2018-2023) & (US$/Unit)
Table 99. Global Candida Infections Drugs Average Price by Application (2024-2029) & (US$/Unit)
Table 100. North America Candida Infections Drugs Sales Quantity by Type (2018-2023) & (K Units)
Table 101. North America Candida Infections Drugs Sales Quantity by Type (2024-2029) & (K Units)
Table 102. North America Candida Infections Drugs Sales Quantity by Application (2018-2023) & (K Units)
Table 103. North America Candida Infections Drugs Sales Quantity by Application (2024-2029) & (K Units)
Table 104. North America Candida Infections Drugs Sales Quantity by Country (2018-2023) & (K Units)
Table 105. North America Candida Infections Drugs Sales Quantity by Country (2024-2029) & (K Units)
Table 106. North America Candida Infections Drugs Consumption Value by Country (2018-2023) & (USD Million)
Table 107. North America Candida Infections Drugs Consumption Value by Country (2024-2029) & (USD Million)
Table 108. Europe Candida Infections Drugs Sales Quantity by Type (2018-2023) & (K Units)
Table 109. Europe Candida Infections Drugs Sales Quantity by Type (2024-2029) & (K Units)
Table 110. Europe Candida Infections Drugs Sales Quantity by Application (2018-2023) & (K Units)
Table 111. Europe Candida Infections Drugs Sales Quantity by Application (2024-2029) & (K Units)
Table 112. Europe Candida Infections Drugs Sales Quantity by Country (2018-2023) & (K Units)
Table 113. Europe Candida Infections Drugs Sales Quantity by Country (2024-2029) & (K Units)
Table 114. Europe Candida Infections Drugs Consumption Value by Country (2018-2023) & (USD Million)
Table 115. Europe Candida Infections Drugs Consumption Value by Country (2024-2029) & (USD Million)
Table 116. Asia-Pacific Candida Infections Drugs Sales Quantity by Type (2018-2023) & (K Units)
Table 117. Asia-Pacific Candida Infections Drugs Sales Quantity by Type (2024-2029) & (K Units)
Table 118. Asia-Pacific Candida Infections Drugs Sales Quantity by Application (2018-2023) & (K Units)
Table 119. Asia-Pacific Candida Infections Drugs Sales Quantity by Application (2024-2029) & (K Units)
Table 120. Asia-Pacific Candida Infections Drugs Sales Quantity by Region (2018-2023) & (K Units)
Table 121. Asia-Pacific Candida Infections Drugs Sales Quantity by Region (2024-2029) & (K Units)
Table 122. Asia-Pacific Candida Infections Drugs Consumption Value by Region (2018-2023) & (USD Million)
Table 123. Asia-Pacific Candida Infections Drugs Consumption Value by Region (2024-2029) & (USD Million)
Table 124. South America Candida Infections Drugs Sales Quantity by Type (2018-2023) & (K Units)
Table 125. South America Candida Infections Drugs Sales Quantity by Type (2024-2029) & (K Units)
Table 126. South America Candida Infections Drugs Sales Quantity by Application (2018-2023) & (K Units)
Table 127. South America Candida Infections Drugs Sales Quantity by Application (2024-2029) & (K Units)
Table 128. South America Candida Infections Drugs Sales Quantity by Country (2018-2023) & (K Units)
Table 129. South America Candida Infections Drugs Sales Quantity by Country (2024-2029) & (K Units)
Table 130. South America Candida Infections Drugs Consumption Value by Country (2018-2023) & (USD Million)
Table 131. South America Candida Infections Drugs Consumption Value by Country (2024-2029) & (USD Million)
Table 132. Middle East & Africa Candida Infections Drugs Sales Quantity by Type (2018-2023) & (K Units)
Table 133. Middle East & Africa Candida Infections Drugs Sales Quantity by Type (2024-2029) & (K Units)
Table 134. Middle East & Africa Candida Infections Drugs Sales Quantity by Application (2018-2023) & (K Units)
Table 135. Middle East & Africa Candida Infections Drugs Sales Quantity by Application (2024-2029) & (K Units)
Table 136. Middle East & Africa Candida Infections Drugs Sales Quantity by Region (2018-2023) & (K Units)
Table 137. Middle East & Africa Candida Infections Drugs Sales Quantity by Region (2024-2029) & (K Units)
Table 138. Middle East & Africa Candida Infections Drugs Consumption Value by Region (2018-2023) & (USD Million)
Table 139. Middle East & Africa Candida Infections Drugs Consumption Value by Region (2024-2029) & (USD Million)
Table 140. Candida Infections Drugs Raw Material
Table 141. Key Manufacturers of Candida Infections Drugs Raw Materials
Table 142. Candida Infections Drugs Typical Distributors
Table 143. Candida Infections Drugs Typical Customers
List of Figures
Figure 1. Candida Infections Drugs Picture
Figure 2. Global Candida Infections Drugs Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 3. Global Candida Infections Drugs Consumption Value Market Share by Type in 2022
Figure 4. Azole Examples
Figure 5. Nystatin Examples
Figure 6. Other Examples
Figure 7. Global Candida Infections Drugs Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
Figure 8. Global Candida Infections Drugs Consumption Value Market Share by Application in 2022
Figure 9. Beriberi Examples
Figure 10. Jock Itch Examples
Figure 11. Vaginal Infection Examples
Figure 12. Other Examples
Figure 13. Global Candida Infections Drugs Consumption Value, (USD Million): 2018 & 2022 & 2029
Figure 14. Global Candida Infections Drugs Consumption Value and Forecast (2018-2029) & (USD Million)
Figure 15. Global Candida Infections Drugs Sales Quantity (2018-2029) & (K Units)
Figure 16. Global Candida Infections Drugs Average Price (2018-2029) & (US$/Unit)
Figure 17. Global Candida Infections Drugs Sales Quantity Market Share by Manufacturer in 2022
Figure 18. Global Candida Infections Drugs Consumption Value Market Share by Manufacturer in 2022
Figure 19. Producer Shipments of Candida Infections Drugs by Manufacturer Sales Quantity ($MM) and Market Share (%): 2021
Figure 20. Top 3 Candida Infections Drugs Manufacturer (Consumption Value) Market Share in 2022
Figure 21. Top 6 Candida Infections Drugs Manufacturer (Consumption Value) Market Share in 2022
Figure 22. Global Candida Infections Drugs Sales Quantity Market Share by Region (2018-2029)
Figure 23. Global Candida Infections Drugs Consumption Value Market Share by Region (2018-2029)
Figure 24. North America Candida Infections Drugs Consumption Value (2018-2029) & (USD Million)
Figure 25. Europe Candida Infections Drugs Consumption Value (2018-2029) & (USD Million)
Figure 26. Asia-Pacific Candida Infections Drugs Consumption Value (2018-2029) & (USD Million)
Figure 27. South America Candida Infections Drugs Consumption Value (2018-2029) & (USD Million)
Figure 28. Middle East & Africa Candida Infections Drugs Consumption Value (2018-2029) & (USD Million)
Figure 29. Global Candida Infections Drugs Sales Quantity Market Share by Type (2018-2029)
Figure 30. Global Candida Infections Drugs Consumption Value Market Share by Type (2018-2029)
Figure 31. Global Candida Infections Drugs Average Price by Type (2018-2029) & (US$/Unit)
Figure 32. Global Candida Infections Drugs Sales Quantity Market Share by Application (2018-2029)
Figure 33. Global Candida Infections Drugs Consumption Value Market Share by Application (2018-2029)
Figure 34. Global Candida Infections Drugs Average Price by Application (2018-2029) & (US$/Unit)
Figure 35. North America Candida Infections Drugs Sales Quantity Market Share by Type (2018-2029)
Figure 36. North America Candida Infections Drugs Sales Quantity Market Share by Application (2018-2029)
Figure 37. North America Candida Infections Drugs Sales Quantity Market Share by Country (2018-2029)
Figure 38. North America Candida Infections Drugs Consumption Value Market Share by Country (2018-2029)
Figure 39. United States Candida Infections Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 40. Canada Candida Infections Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 41. Mexico Candida Infections Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 42. Europe Candida Infections Drugs Sales Quantity Market Share by Type (2018-2029)
Figure 43. Europe Candida Infections Drugs Sales Quantity Market Share by Application (2018-2029)
Figure 44. Europe Candida Infections Drugs Sales Quantity Market Share by Country (2018-2029)
Figure 45. Europe Candida Infections Drugs Consumption Value Market Share by Country (2018-2029)
Figure 46. Germany Candida Infections Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 47. France Candida Infections Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 48. United Kingdom Candida Infections Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 49. Russia Candida Infections Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 50. Italy Candida Infections Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 51. Asia-Pacific Candida Infections Drugs Sales Quantity Market Share by Type (2018-2029)
Figure 52. Asia-Pacific Candida Infections Drugs Sales Quantity Market Share by Application (2018-2029)
Figure 53. Asia-Pacific Candida Infections Drugs Sales Quantity Market Share by Region (2018-2029)
Figure 54. Asia-Pacific Candida Infections Drugs Consumption Value Market Share by Region (2018-2029)
Figure 55. China Candida Infections Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 56. Japan Candida Infections Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 57. Korea Candida Infections Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 58. India Candida Infections Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 59. Southeast Asia Candida Infections Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 60. Australia Candida Infections Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 61. South America Candida Infections Drugs Sales Quantity Market Share by Type (2018-2029)
Figure 62. South America Candida Infections Drugs Sales Quantity Market Share by Application (2018-2029)
Figure 63. South America Candida Infections Drugs Sales Quantity Market Share by Country (2018-2029)
Figure 64. South America Candida Infections Drugs Consumption Value Market Share by Country (2018-2029)
Figure 65. Brazil Candida Infections Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 66. Argentina Candida Infections Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 67. Middle East & Africa Candida Infections Drugs Sales Quantity Market Share by Type (2018-2029)
Figure 68. Middle East & Africa Candida Infections Drugs Sales Quantity Market Share by Application (2018-2029)
Figure 69. Middle East & Africa Candida Infections Drugs Sales Quantity Market Share by Region (2018-2029)
Figure 70. Middle East & Africa Candida Infections Drugs Consumption Value Market Share by Region (2018-2029)
Figure 71. Turkey Candida Infections Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 72. Egypt Candida Infections Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 73. Saudi Arabia Candida Infections Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 74. South Africa Candida Infections Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 75. Candida Infections Drugs Market Drivers
Figure 76. Candida Infections Drugs Market Restraints
Figure 77. Candida Infections Drugs Market Trends
Figure 78. Porters Five Forces Analysis
Figure 79. Manufacturing Cost Structure Analysis of Candida Infections Drugs in 2022
Figure 80. Manufacturing Process Analysis of Candida Infections Drugs
Figure 81. Candida Infections Drugs Industrial Chain
Figure 82. Sales Quantity Channel: Direct to End-User vs Distributors
Figure 83. Direct Channel Pros & Cons
Figure 84. Indirect Channel Pros & Cons
Figure 85. Methodology
Figure 86. Research Process and Data Source
Please feel free to write an email to us or to use our electronic ticketing system.
